Working… Menu

Low-dose VS High-dose IV Cyclophosphamide for Proliferative LN in Children (Low/highIVCY)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01861561
Recruitment Status : Terminated (The duration of the study is longer than 5 years and we can not recruit the participants to the target number.)
First Posted : May 23, 2013
Last Update Posted : September 4, 2020
Information provided by (Responsible Party):
Mahidol University

Brief Summary:
Proliferative lupus nephritis (LN)is the predominant cause of morbidity and mortality in juvenile Systemic Lupus Erythematosus (SLE). Induction therapy with high-dose intravenous cyclophosphamide can improve renal outcomes, but considerably associated with infection. Although severe infection is the significant complication related to poorer prognosis for juvenile SLE patients in Asia, cyclophosphamide is still commonly used as the drug of choice for severe lupus nephritis. Euro-Lupus Nephritis Trial demonstrated low-dose intravenous cyclophosphamide regimen followed by azathioprine achieved good clinical results comparable with obtained high-dose regimen. There was lower number of severe infection episodes, but no significant difference. Recent studies applied low dose of cyclophosphamide (500 mg/m2/dose or 500 mg/dose)in young patients and showed good renal response. Low-dose intravenous cyclophosphamide regimen might promote non-inferior renal remission whereas decrease risk of serious infection and improve overall patient outcomes.

Condition or disease Intervention/treatment Phase
Renal Insufficiency Infection Drug: Low-dose intravenous cyclophosphamide Drug: High-dose intravenous cyclophosphamide Phase 4

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 43 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Efficacy and Infectious Complications of Induction Therapy With Low-dose Versus High-dose Intravenous Cyclophosphamide for Proliferative Lupus Nephritis in Children
Study Start Date : May 2013
Actual Primary Completion Date : May 2019
Actual Study Completion Date : May 2019

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: Low-dose intravenous cyclophosphamide
Low-dose intravenous cyclophosphamide 500 mg/m2/dose every 4 weeks/months for 7 doses. Total duration is 6 months for the induction treatment.
Drug: Low-dose intravenous cyclophosphamide
Intravenous cyclophosphamide 500 mg/m2/dose every 4 weeks/months, total 7 doses
Other Name: Cytoxan

Active Comparator: High-dose intravenous cyclophosphamide
High-dose intravenous cyclophosphamide 1,000 mg/m2/dose, the first dose will be started with 500 mg/m2/dose and steped up to 750 mg/m2/dose for the second dose. Then the dosage will be increased to 1,000 mg/m2/dose for the third dose and continued the dosage through the seventh dose. Total duration is 6 months for the induction treatment.
Drug: High-dose intravenous cyclophosphamide

Intravenous cyclophosphamide every 4 weeks/months, total in 7 doses:

the 1st dose-500 mg/m2/dose,the 2nd dose-750 mg/m2/dose, the 3rd-7th doses- 1,000 mg/m2/dose with the maximum dose at 1,500 mg/dose

Other Name: Cytoxan

Primary Outcome Measures :
  1. renal response [ Time Frame: at 6 months of the treatment ]

    3 main renal parameters: renal function(eCCl),proteinuria(spot urine protein/creatinine ratio, UPCR), and urine sediment (rbc,wbc,and casts) 'renal remission'

    • complete- normal renal function, UPCR<0.2, and normal urine sediment(rbc<5,wbc<5/HPF,and no cast)
    • partial- at least 50%improvement in 2 main parameters with UPCR <= 1.0 and without worsening of remaining main parameter

Secondary Outcome Measures :
  1. infection [ Time Frame: within 6 months ]

    infectious episode classified in 3 levels

    • mild infection - the infection that is not serious and the patient could be treated with oral antimicrobial agent in outpatient clinic
    • moderate infection - the infection that the patient need admission or intravenous antimicrobial agent
    • serious infection - the infection that the patient is critically ill and need ICU care

Other Outcome Measures:
  1. Patient well being [ Time Frame: at 0,1,3 and 6 months of the treatment ]
    using visual analogue scale (VAS 0-10)for self assessment their well being

  2. SLE disease activity index score [ Time Frame: at 0,1,3 and 6 months of the treatment ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   up to 15 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Child up to 15 years of age who fulfilled the 1997 updating the American College of Rheumatology revised criteria for the classification of SLE and his or her renal biopsy reveals lupus nephritis class III or IV regarding to International Society of Nephrology/Renal Pathology Society revision on the classification of the lupus nephritis.

Exclusion Criteria:

  • patient who has prior renal insufficiency due to chronic kidney disease other than lupus nephritis
  • patient who has the history of cyclophosphamide hypersensitivity
  • patient who has prior cyclophosphamide or mycophenolate mofetil administration within 6 months
  • patient who is pregnant

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01861561

Layout table for location information
Nephrology division, Department of Pediatrics, Siriraj Hospital
Bangkoknoi, Bangkok, Thailand, 10700
Sponsors and Collaborators
Mahidol University
Layout table for investigator information
Principal Investigator: Nuntawan Piyaphanee, MD Siriraj Hospital
Study Director: Anirut Pattaragarn, MD Siriraj Hospital
Layout table for additonal information
Responsible Party: Mahidol University Identifier: NCT01861561    
Other Study ID Numbers: 125/2556(EC2)
First Posted: May 23, 2013    Key Record Dates
Last Update Posted: September 4, 2020
Last Verified: September 2020
Additional relevant MeSH terms:
Layout table for MeSH terms
Renal Insufficiency
Kidney Diseases
Urologic Diseases
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Antirheumatic Agents
Antineoplastic Agents, Alkylating
Alkylating Agents
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Myeloablative Agonists